Clinical Trial Update: Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for rovalpituzumab tesirine (SC16LD6.5) in recurrent small cell lung cancer across Phase 1 and Phase 2, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• rovalpituzumab tesirine (rovalpituzumab tesirine)

Snippet

Sponsor: Stemcentrx | Conditions: Recurrent Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-07-11